Supramolecular Application of Cyclodextrin and Their Novel Derivatives: A Therapeutic Approach to the Treatment of Chronic Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 277
Special Issue Editors
2. Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
Interests: drug delivery systems; medicinal chemistry; natural products
Special Issues, Collections and Topics in MDPI journals
Interests: pharmacology and toxicology; analytical pharmacognosy; anti inflammatory; phytochemistry; medicinal plant
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleague,
Cyclodextrins (CDs) are oligosaccharides that are widely used as carrier systems for bioactive compounds due to their ability to form host–guest inclusion complexes. Hundreds of modified CDs are commercially available for use in research and industrial applications. However, only a limited number of modified cyclodextrins are currently used, mainly as pharmaceutical excipients. These include cyclodextrins with substituted hydroxypropyl (HP), methyl (M) and sulfobutylether (SBE) groups, for instance.
There have been many reports concerning the formation of pharmaceutical and cyclodextrin inclusion complexes, as the therapeutic treatment of chronic diseases with these complexes is interesting considering the complexation effect between the host and the modified CD. Due to their low aqueous solubilizations and decreased bioavailability within living organisms, many drugs used for the treatment of diabetes, cancer, cardiovascular diseases and arthritis are studied using CDs to enable the permanent therapeutic effect of the drug in a constant and controlled manner over time, without elimination from the organism and increasing the chemical stability of the active compounds.
Therefore, we invite researchers to contribute their experimental work through molecular modeling studies of the active compounds and these supramolecular structures, and pharmacological evaluations of the potential treatment of chronic diseases using CD derivatives that will support an effective administration of active compounds in a controlled manner.
Prof. Dr. Eduardo Sobarzo-Sánchez
Prof. Dr. Esra Küpeli Akkol
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cyclodextrin
- supramolecular devices
- inclusion complex
- drug delivery
- chronic diseases
